LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M

Shots: LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) As per the deal, Tanabe Pharma will receive up to $435M in upfront & near-term milestone payments together with potential downstream milestones and tiered royalties on net…

ByRidhi RastogiAugust 18, 2026

NEWS

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

Shots: OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening As…

ByRidhi RastogiAugust 17, 2026

NEWS

PTC Therapeutics to Acquire Sangamo Therapeutics’ ST-920 Gene Therapy Program

Shots: PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics through a competitive bankruptcy auction As per the terms, PTC Therapeutics will pay $111M upfront, with up to $100M in contingent milestone payments tied to certain regulatory approvals; expected to…

ByRidhi RastogiAugust 13, 2026

NEWS

Mereo BioPharma and Sentynl Therapeutics Ink ~$475M Pact for Alvelestat

Shots: Sentynl, a subsidiary of Zydus, has entered into an option & license agreement with Mereo for the US commercial & global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Sentynl will have an exclusive option to license alvelestat in the US, while Mereo retains ex-US commercial rights; Sentynl will also hold…

ByRidhi RastogiAugust 12, 2026

NEWS

Jazz Pharmaceuticals to Acquire Actio Biosciences for ~$1.32B

Shots: Jazz Pharmaceuticals has entered into a definitive agreement to acquire Actio Biosciences, incl. its asset ABS-1230 for the treatment of KCNT1+ epilepsy; closing expected by Q4’26 Under the merger, Actio shareholders will receive $820M upfront & ~$500M in approval and sales milestones. Actio will spin out a new private company, excl. ABS-1230, which remains…

ByRidhi RastogiAugust 10, 2026

NEWS

Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics

Shots: Oculis will acquire Accure’s worldwide development & commercial rights to Privosegtor (ACT-01), terminating its existing license & giving Oculis greater control and economic upside as the neuro-ophthalmology asset advances Deal also incl. ACT-02, a preclinical neurology candidate. Total consideration incl. $3.8M upfront cash & ~2.05M Oculis shares, incl. milestone-linked shares. Closing is expected by…

ByRidhi RastogiAugust 10, 2026

NEWS

Almirall Partners with CrystalO to Advance Novel Small Molecules in Medical Dermatology

Shots: Almirall & CrystalO have partnered to advance drug discovery research in medical dermatology, leveraging CrystalO's scientific expertise in ion channels with Almirall's experience in medical dermatology R&D As per the deal, CrystalO will use its AI & structure-based drug discovery platform for compound discovery, optimization, IND-enabling studies, & early clinical development through PoC. Almirall…

ByRidhi RastogiAugust 10, 2026

NEWS

Innovent and Daiichi Sankyo Partner to Commercialize Vanflyta in China

Shots: Innovent Biologics has entered into an exclusive agreement with Daiichi Sankyo to commercialize Vanflyta (quizartinib) in China As per the deal, Daiichi Sankyo will handle the development, manufacturing & supply of Vanflyta while Innovent will hold sole commercialization rights for Vanflyta in China Vanflyta was approved in China in Jun’26 for newly diagnosed FLT3-ITD-positive AML in…

ByRidhi RastogiAugust 10, 2026

NEWS

Ono and Mediar Partner to Develop Antibody Therapies for Fibro-Inflammatory Diseases

Shots: Ono has entered into a drug discovery partnership & option agreement with Mediar Therapeutics to develop novel antibody therapeutics for fibro-inflammatory diseases As per the deal, Mediar will conduct research using its fibrosis-focused research platform, while Ono will gain exclusive worldwide option rights to select candidates for development, manufacturing, & commercialization The partnership will…

ByRidhi RastogiAugust 7, 2026

NEWS

Alteogen Licenses ALT-B4 to a Global Pharmaceutical Company in a ~$365M Deal

Shots: Alteogen has entered into an exclusive license agreement with a global pharmaceutical company to develop & commercialize a SC formulation of a biologic product utilizing ALT-B4 (berahyaluronidase alfa) As per the deal, the company will acquire exclusive global rights to the SC formulation of a biologic product. In exchange, Alteogen will receive ~$365M, incl.…

ByRidhi RastogiAugust 6, 2026

LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

PTC Therapeutics to Acquire Sangamo Therapeutics’ ST-920 Gene Therapy Program

Mereo BioPharma and Sentynl Therapeutics Ink ~$475M Pact for Alvelestat

Jazz Pharmaceuticals to Acquire Actio Biosciences for ~$1.32B

Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics

Almirall Partners with CrystalO to Advance Novel Small Molecules in Medical Dermatology

Innovent and Daiichi Sankyo Partner to Commercialize Vanflyta in China

Ono and Mediar Partner to Develop Antibody Therapies for Fibro-Inflammatory Diseases

Alteogen Licenses ALT-B4 to a Global Pharmaceutical Company in a ~$365M Deal

Contact US

FOLLOW US